Beta Bionics, is partnering with Abbott to make life a little easier for people with type 1 diabetes. The collaboration will bring Abbott’s FreeStyle Libre® 3 Plus continuous glucose monitor (CGM) together with Beta Bionics’ iLet Bionic Pancreas, an automated insulin delivery system designed to take much of the guesswork out of managing the condition.
The iLet Bionic Pancreas is unique in that it handles insulin dosing automatically. By connecting it to the FreeStyle Libre 3 Plus, which provides glucose readings every minute, the iLet can adjust insulin levels without requiring users to input carb counts or make manual corrections throughout the day. All users need to do to get started is input their weight, and the system takes care of the rest.
“Our goal has always been to make diabetes management simpler and less burdensome,” said Sean Saint, CEO of Beta Bionics. “This partnership with Abbott gives people more choice when it comes to the tools they use to manage their diabetes, allowing them to customize their experience based on what works best for them.”
Jared Watkin, who leads Abbott’s diabetes care division, highlighted the importance of giving people more freedom to focus on their lives, not just their condition. “By working with Beta Bionics, we’re creating a system that’s not only accurate and easy to use but also gives users more flexibility in how they manage their health.”
The integration of the iLet Bionic Pancreas with Abbott’s FreeStyle Libre 3 Plus is expected to launch in late 2024. The update will be available through pharmacies and medical equipment distributors, making it easier for users to access both the technology and their supplies.
This collaboration is part of a broader effort to streamline diabetes care, offering people with type 1 diabetes more convenience and fewer day-to-day responsibilities when it comes to managing their health.